Announcement • Nov 19
Raphael Pharmaceutical Inc. Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis R Raphael Pharmaceutical Inc. announced the filing of a provisional patent application with the United States Patent and Trademark Office. The application covers the use of the Company's highly purified cannabinoid-based technology platform in the treatment of neutrophil-dominant autoimmune diseases, including its lead product candidate for rheumatoid arthritis (RA), as well as psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement, and gout. Raphael previously announced positive proof-of-concept clinical study results for its cannabinoid-based formula for the management of RA. The study was successfully completed in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. No adverse effects were reported throughout the trial. The provisional patent application, titled, "R Raphael Pharmaceutical Inc. /Rambam MedTech Formula for Treating Neutrophil-Dominant Autoimmune Diseases (including RA)" (No. 63/911,729), was filed jointly with the Medical Cannabis Research and Innovation Center (MCRIC) at Rambam Health Care Campus - one of the world's leading university hospitals. Raphael and Rambam have collaborated under a sponsored research agreement signed in 2019, granting Raphael exclusive access to Rambam's world-class cannabinoid research and development program, led by Dr. Igal Louria-Hayon, who serves as both Chief Technology Officer (CTO) of Raphael and Head of the Medical Cannabis Research and innovation Center at Rambam Health Care campus. Dr. Louria-Hayon is a global expert in cannabinoid research and cell-to-cell communication. Key Findings from the Proof-of-Concept Clinical Study: Raphael Pharmaceutical utilizes a highly purified cannabinoid formulation derived from the hemp plant, entirely free of psychoactive cannabis components, with exceptional anti-inflammatory potential. The formulation is administered orally and demonstrated no side effects. It is designed to interact with the human endocannabinoid system by activating cannabinoid receptors expressed on immune cells. In 2025, the Company announced positive Proof-of-Concept clinical results for the use of its cannabinoid-based formula in the treatment of RA. The eight-week IRB-approved study conducted in the United States showed significant improvements in pain, sleep quality, and overall well-being, which became evident as early as week four and persisted through the end of the trial. This included a reduction in DAS28 scores from high disease activity to moderate disease severity. 
